Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY:NVS)

129.14 -1.22 (-0.94%)
Official Closing Price Updated: 7:00 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
50 51 Next >
AMC Stock Alert: Adam Aron Teases New Chocolate, Wine Brands for AMC
AMC Entertainment (AMC) stock is a hot topic on Friday after the movie theater chain's CEO teased that new products are on the way. 
Via InvestorPlace
Why Is Canopy Growth (CGC) Stock Up 14% Today?
Canopy Growth (CGC) stock is rising higher on Friday after the cannabis company announced it won't fund BioSteel Sports Nutrition any longer. 
Via InvestorPlace
Topics Cannabis
NVS Stock Alert: Novartis Shareholders Approve Sandoz Spinoff
Novartis (NVS) stock is rising higher on Friday after the company announced approval for the spinoff of its generic drugs business Sandoz. 
Via InvestorPlace
Instacart Mulls IPO Price Hike After Arm's Stellar Debut, UAW Launches Historic Simultaneous Strike, China Sanctions Lockheed Martin & Northrop Grumman Concerning Taiwan Arms Sales: Today's Top Stories
Wall Street Journal 
Via Benzinga
Topics Initial Public Offering
2 Dividend Stocks to Buy and Hold Forever
These companies' prospects look secure. 
Via The Motley Fool
Price Over Earnings Overview: Novartis
 
Via Benzinga
Peering Into Novartis's Recent Short Interest
 
Via Benzinga
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
Sandoz Pushes Product Launch Plans As Novartis Shareholders Approve The Spin-Off
At an Extraordinary General Meeting, Novartis AG's (NYSE: NVS) shareholders  
Via Benzinga
AI Integration In Biotech & Pharma: Companies Positioned To Benefit
The convergence of artificial intelligence (AI) with the biotech and pharmaceutical sectors is ushering in a new era of innovation. AI is catalyzing transformations from drug discovery to patient care.... 
Via Benzinga
Topics Artificial Intelligence
Qualcomm-Apple's Chip Supply Agreement, Alleged Report About AstraZeneca CEO Sir Pascal Soriot's Intention To Step Down, Apple & Google Face Off in Antitrust Showdown: Today's Top Stories
Benzinga Qualcomm Announces Chip Supply Agreement With Apple 
Via Benzinga
Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis
Sandoz, a generic and biosimilar medicines unit of Novartis AG (NYSE: NVS), has  
Via Benzinga
AI 2.0 is Here: How to Invest in a Generational Opportunity
AI is sweeping the world but don't confuse apples with oranges; here's a look at the top 5 advancements in AI and who is using it. 
Via MarketBeat
Topics Artificial Intelligence Supply Chain
Could This Biosimilar Drug Be Novartis' Next Blockbuster?
Novartis expects to submit regulatory applications for its biosimilar soon. 
Via The Motley Fool
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs? 
Via The Motley Fool
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
Via MarketBeat
Topics Economy
Biden Administration Vs. Big Pharma: What the Legal Showdown Means for Your Wallet
The Biden administration's move to lower drug prices has prompted a flurry of legal challenges. 
Via Benzinga
Sex Hormones Market to See Huge Growth by 2028 : Novartis, Sanofi, AstraZeneca, Merck
Sex Hormones- Comprehensive Study by Type (Progesterone, Testosterone, Drospirenone), Application (Topical, Inhalation, Injection, Others) Players and Region - Global Market Outlook to 2027 
Via SBWire
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations. 
Via The Motley Fool
Transdermal Drug Patches Market to See Huge Growth : Novartis, Mylan, Accrux
Stay up-to-date with Transdermal Drug Patches Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
Important Data Ahead, Tesla Turning On Massive Nvidia Cluster, 10 Drugs Name For Price Cuts
To gain an edge, this is what you need to know today. 
Via Benzinga
Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle
The Centers for Medicare and Medicaid Services unveiled the first ten drugs subject to price negotiations under President Joe Biden's Inflation Reduction Act, including: 
Via Benzinga
Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts
The Biden administration is planning to negotiate the prices of 10 drugs in 2026. 
Via Investor's Business Daily
3 AI Stocks With the Potential to Transform Your Financial Future
Are you looking to invest in AI stocks? Here are three picks with the potential to transform your financial future. 
Via InvestorPlace
Topics Artificial Intelligence
3 Emerging Market Stocks to Buy in August
These three emerging market stocks to buy in August will have very strong, positive catalysts going forward. 
Via InvestorPlace
Exelixis' Lead Cancer Treatment Delivers Another Surprise, Though Analyst Finds Commercial Opportunity In Pancreatic Neuroendocrine Modest
Thursday, Exelixis Inc (NASDAQ: EXEL) announced that the Alliance for Clinical Trials in Oncology independent Data and Safety Monitoring Board (DSMB) unanimously recommended to unblind and stop the... 
Via Benzinga
Cheaper Version Of Blockbuster Arthritis Treatment Humira - CVS Health Teams With Sandoz
CVS Health Corp (NYSE: CVS) has launched Cordavis, a wholly-owned subsidiary, to work directly with manufacturers to commercialize and/or co-produce biosimilar  
Via Benzinga
Could This Medicine Be the Next Winner for Novartis?
The Swiss drugmaker recently reported that a drug candidate met the primary endpoints in phase 3 clinical trials. 
Via The Motley Fool
Gold Rush In Weight Loss Industry Impacts Retailers With Pharmacy Businesses
Retailers with pharmacy businesses, including major players like Walmart Inc (NYSE: WMT), Kroger Company (NYSE: KR), and Rite Aid Corp (NYSE: 
Via Benzinga
A Comprehensive Study Exploring Breast Cancer Drugs Market : Key Players- Sanofi, Novartis, Lilly
The Global Breast Cancer Drugs Market offers energetic visions to conclude market size, opportunities, growth pattern, and competitive surroundings. The research is derived through primary and... 
Via SBWire
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
50 51 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.